Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Saxagliptin - AstraZeneca

Next Previous
X
Search
Drug Profile

Saxagliptin - AstraZeneca

Alternative Names: BMS-477118; Onglyza; OPC-262

Latest Information Update: 02 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; Bristol-Myers Squibb; Otsuka Pharmaceutical
  • Class Adamantanes; Antihyperglycaemics; Azabicyclo compounds; Dipeptides; Nitriles; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 03 Jan 2024 AstraZeneca completes phase III trials for Type 2 diabetes mellitus (Adjunctive treatment, In adolescents, In children) in USA, Australia, Argentina, United Kingdom, Ukraine, Turkey, Thailand, Taiwan, Russia, Romania, Philippines, New Zealand, Mexico, Malaysia, South Korea, Italy, Israel, India, Colombia, Chile, Brazil, Canada, Finland, Poland (PO) (NCT03199053)
  • 08 Mar 2022 Saxagliptin is still in phase III trials for Type 2 diabetes mellitus (Adjunctive treatment, In adolescents, In children) in USA, Australia, Argentina, United Kingdom, Ukraine, Turkey, Thailand, Taiwan, Russia, Romania, Philippines, New Zealand, Mexico, Malaysia, South Korea, Italy, Israel, India, Colombia, Chile, Brazil, Canada, Finland, Poland (PO) (NCT03199053)
  • 13 Nov 2020 Efficacy results from a phase III trial for Type 2 diabetes mellitus presented at 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top